Clinitech Laboratory Limited (BOM:544220)
India · Delayed Price · Currency is INR 37.80
0.00 (0.00%)
At close: May 29, 2026
Clinitech Laboratory Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 94.91 | 82.35 | 64.03 | 63.48 | 63.84 |
Other Revenue | 1.88 | - | - | - | - |
| 96.79 | 82.35 | 64.03 | 63.48 | 63.84 | |
Revenue Growth (YoY) | 17.54% | 28.61% | 0.87% | -0.58% | 40.19% |
Cost of Revenue | 30.89 | 18.81 | 13.78 | 14.14 | 18.18 |
Gross Profit | 65.91 | 63.54 | 50.25 | 49.33 | 45.66 |
Selling, General & Admin | 30.84 | 29.23 | 23.53 | 20.32 | 17.79 |
Other Operating Expenses | 28.42 | 25.69 | 16.69 | 15.49 | 17.19 |
Operating Expenses | 59.25 | 59.41 | 44.61 | 40.27 | 38.78 |
Operating Income | 6.65 | 4.12 | 5.64 | 9.06 | 6.88 |
Interest Expense | -0.69 | -0.43 | -0.72 | -0.58 | -0.42 |
Interest & Investment Income | - | 1.3 | 0.1 | 0.08 | 0.06 |
Earnings From Equity Investments | - | - | - | 0.04 | 0.11 |
Other Non Operating Income (Expenses) | - | -0.12 | -0.07 | 0.04 | 0.4 |
EBT Excluding Unusual Items | 5.96 | 4.87 | 4.95 | 8.64 | 7.02 |
Gain (Loss) on Sale of Assets | - | 0.68 | 0.11 | - | -0 |
Pretax Income | 5.96 | 5.55 | 5.05 | 8.64 | 7.02 |
Income Tax Expense | 1.81 | 1.6 | 1.34 | 2.51 | 1.9 |
Earnings From Continuing Operations | 4.15 | 3.95 | 3.71 | 6.13 | 5.13 |
Minority Interest in Earnings | 0.03 | - | - | - | - |
Net Income | 4.18 | 3.95 | 3.71 | 6.13 | 5.13 |
Net Income to Common | 4.18 | 3.95 | 3.71 | 6.13 | 5.13 |
Net Income Growth | 5.88% | 6.33% | -39.45% | 19.61% | 27.39% |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 |
Shares Change (YoY) | 9.70% | 32.88% | 4.44% | - | - |
EPS (Basic) | 1.83 | 1.90 | 2.37 | 4.09 | 3.42 |
EPS (Diluted) | 1.83 | 1.90 | 2.37 | 4.09 | 3.42 |
EPS Growth | -3.49% | -19.98% | -42.03% | 19.61% | 27.39% |
Free Cash Flow | -16.18 | -20.43 | -24.88 | 9.68 | -5.58 |
Free Cash Flow Per Share | -7.09 | -9.82 | -15.88 | 6.45 | -3.72 |
Gross Margin | 68.09% | 77.16% | 78.47% | 77.72% | 71.52% |
Operating Margin | 6.87% | 5.01% | 8.80% | 14.27% | 10.77% |
Profit Margin | 4.32% | 4.79% | 5.80% | 9.66% | 8.03% |
Free Cash Flow Margin | -16.72% | -24.81% | -38.86% | 15.24% | -8.73% |
EBITDA | 11.76 | 8.62 | 9.97 | 13.52 | 10.69 |
EBITDA Margin | 12.15% | 10.47% | 15.57% | 21.30% | 16.74% |
D&A For EBITDA | 5.1 | 4.5 | 4.34 | 4.46 | 3.81 |
EBIT | 6.65 | 4.12 | 5.64 | 9.06 | 6.88 |
EBIT Margin | 6.87% | 5.00% | 8.80% | 14.27% | 10.77% |
Effective Tax Rate | 30.41% | 28.83% | 26.52% | 29.02% | 27.00% |
Revenue as Reported | 96.79 | 84.63 | 64.39 | 63.63 | 64.57 |
Advertising Expenses | - | 0.62 | 0.65 | - | - |